Study: Eplerenone cuts heart failure risk in patients with diabetes

08/29/2011 | Medscape (free registration)

Eplerenone treatment helped reduce the risks of cardiovascular mortality and heart-failure hospitalization in patients with diabetes, experts reported at the 2011 Congress of the European Society of Cardiology. The U.S. and European guidelines may soon be updated to include recommendations for eplerenone use in patients with diabetes, as spironolactone treatment has been associated with worse endothelial function and higher glucose levels in patients, experts said.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA